Locket Healthcare "Exports Skin Regeneration Treatment Platform to Argentina"
[Asia Economy Reporter Byun Seon-jin] Biohealthcare company Rokit Healthcare announced on the 28th that it has signed a 5-year skin regeneration treatment platform supply contract worth $87.3 million (approximately 124 billion KRW) with Argentine pharmaceutical manufacturer Laboratorio Varifarma S.A.
Established in 1995, Laboratorio Varifarma is a company with a scale of 100 billion KRW producing pharmaceuticals related to oncology, multiple sclerosis, rheumatoid arthritis, acromegaly, and diabetes. Rokit Healthcare provides regenerative medical services for skin, cartilage, and organs through its self-developed autologous tissue regeneration platform technology.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Over 7,000 Residents Evacuate Urgently" Magnitude 5.2 Earthquake Leaves 2 Dead, 6 Injured... What Happened in China?
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
A company representative said, “The contract with Laboratorio Varifarma is significant in that it establishes a foothold in the vast South American market following Brazil,” and “discussions are also underway with Chile and Peru, and contracts are expected to be signed soon.” Rokit Healthcare signed a supply contract with Colombia in 2020 and, earlier this year, also signed a supply contract worth approximately 100 billion KRW with Brazilian company 1000Medic.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
